Salarius Pharmaceuticals, Inc. announced that Daniela Y. Santiesteban, Ph.D., Director of Research and Business Development at the company, has been invited to participate in a panel discussion during Noble Capital Markets’ 17th Annual Small & Microcap Investor Conference (NobleCon17). The conference is taking place January 19-21, 2021 over a virtual platform. During the event, Dr. Santiesteban and other panel members will discuss the current status of targeted cancer therapies, as well as the future outlook for research and drug development in the field. The company is developing seclidemstat, a reversible LSD1 inhibitor that is now being studied in two clinical trials — one trial in relapsed/refractory Ewing sarcoma, a rare and deadly pediatric bone and soft tissue cancer, and a second trial in advanced solid tumors (AST). The company expects to establish maximum tolerated dose (MTD) in its Ewing sarcoma trial and advance into the dose-expansion phase of the Ewing sarcoma trial in early 2021. The company also expects to expand the same trial to include additional select sarcomas that share a similar biology to Ewing sarcoma, also known as Ewing-related sarcomas.